PRODUCT MONOGRAPH

VOLTAREN EMULGEL

Diclofenac Diethylamine Gel, 11.6 mg/g (1.16% w/w)

VOLTAREN EMULGEL Back & Muscle Pain

Diclofenac Diethylamine Gel, 11.6 mg/g (1.16% w/w)

VOLTAREN EMULGEL Joint Pain Regular Strength

Diclofenac Diethylamine Gel, 11.6 mg/g (1.16% w/w)

Non-Steroidal Anti-inflammatory Drug (NSAID) Analgesic agent for topical use

Separate Product Monograph available for VOLTAREN EMULGEL Extra Strength and VOLTAREN EMULGEL Joint Pain Extra Strength (Diclofenac diethylamine Gel, 23.2 mg/g /2.32% w/w)

GlaxoSmithKline Consumer Healthcare Inc. 7333 Mississauga Rd. Mississauga, Ontario Canada L5N 6L4 Date of Revision: March 4, 2020

Submission Control No: 226872

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION	
SUMMARY PRODUCT INFORMATION	
INDICATIONS AND CLINICAL USE	
CONTRAINDICATIONS	
WARNINGS AND PRECAUTIONS	
ADVERSE REACTIONS	
DRUG INTERACTIONS	
DOSAGE AND ADMINISTRATION	
OVERDOSAGE	
ACTION AND CLINICAL PHARMACOLOGY	
STORAGE AND STABILITY	
SPECIAL HANDLING INSTRUCTIONS	
	17
DOSAGE FORMS, COMPOSITION AND PACKAGING	
DOSAGE FORMS, COMPOSITION AND PACKAGING PART II: SCIENTIFIC INFORMATION	18
DOSAGE FORMS, COMPOSITION AND PACKAGING PART II: SCIENTIFIC INFORMATION PHARMACEUTICAL INFORMATION CLINICAL TRIALS	18
DOSAGE FORMS, COMPOSITION AND PACKAGING PART II: SCIENTIFIC INFORMATION PHARMACEUTICAL INFORMATION CLINICAL TRIALS DETAILED PHARMACOLOGY	18
DOSAGE FORMS, COMPOSITION AND PACKAGING PART II: SCIENTIFIC INFORMATION PHARMACEUTICAL INFORMATION CLINICAL TRIALS DETAILED PHARMACOLOGY Pharmacokinetics	18
DOSAGE FORMS, COMPOSITION AND PACKAGING PART II: SCIENTIFIC INFORMATION PHARMACEUTICAL INFORMATION CLINICAL TRIALS DETAILED PHARMACOLOGY Pharmacokinetics Percutaneous Absorption, Distribution, Metabolism, Excretion	18
DOSAGE FORMS, COMPOSITION AND PACKAGING PART II: SCIENTIFIC INFORMATION	18
DOSAGE FORMS, COMPOSITION AND PACKAGING PART II: SCIENTIFIC INFORMATION	18
DOSAGE FORMS, COMPOSITION AND PACKAGING PART II: SCIENTIFIC INFORMATION	18
DOSAGE FORMS, COMPOSITION AND PACKAGING PART II: SCIENTIFIC INFORMATION	18
DOSAGE FORMS, COMPOSITION AND PACKAGING PART II: SCIENTIFIC INFORMATION	18
DOSAGE FORMS, COMPOSITION AND PACKAGING PART II: SCIENTIFIC INFORMATION	
DOSAGE FORMS, COMPOSITION AND PACKAGING PART II: SCIENTIFIC INFORMATION	

VOLTAREN EMULGEL, VOLTAREN EMULGEL Back & Muscle Pain and VOLTAREN EMULGEL Joint Pain Regular Strength Diclofenac diethylamine gel 11.6 mg/g (1.16% w/w)

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Topical	Gel / 11.6 mg/g diclofenac diethylamine	Propylene glycol, fragrance (containing benzyl benzoate)
	(1.16% w/w)	For a complete listing see Dosage Forms, Composition and Packaging section.

INDICATIONS AND CLINICAL USE

Adults and adolescents aged 16 years and over:

VOLTAREN EMULGEL, VOLTAREN EMULGEL Back & Muscle Pain and VOLTAREN EMULGEL Joint Pain Regular Strength (diclofenac diethylamine gel 1.16% w/w) are indicated for:

• Relief of pain associated with recent (acute), localized muscle or joint injuries such as sprains, strains or sports injuries (*e.g.* sprain of ankle, strain of shoulder or back muscles). This is typically as an adjunct to other measures such as rest for the relief of discomfort associated with such injuries.

Geriatrics (> 65 years of age):

The usual adult dosage may be used.

Paediatrics (< 16 years of age):

Not for use in children under 16 years of age.

CONTRAINDICATIONS

- Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.
- Hypersensitivity to diclofenac, acetylsalicylic acid or other non-steroidal anti-inflammatory drugs.

- Patients with or without chronic asthma in whom attacks of asthma, angioedema, urticaria or acute rhinitis are precipitated by acetylsalicylic acid or other non-steroidal anti-inflammatory agents.
- Concomitant use of other products containing diclofenac.
- Concomitant use of oral non-steroidal anti-inflammatory drugs (NSAIDs).
- During the last trimester of pregnancy
- Following coronary artery bypass grafting surgery

WARNINGS AND PRECAUTIONS

<u>General</u>

Diclofenac diethylamine gel 1.16% w/w is for topical use only and should be applied only to intact, non-diseased skin and not to skin wounds or open injuries. It should not be used with occlusion. It should not be allowed to come into contact with the eyes, or mucous membranes, and should never be taken by mouth.

VOLTAREN EMULGEL, VOLTAREN EMULGEL Back & Muscle Pain and VOLTAREN EMULGEL Joint Pain Regular Strength (diclofenac diethylamine gel 1.16% w/w) contain propylene glycol and fragrance (containing benzyl benzoate), which may cause mild, localized skin irritation in some people. For a complete list of the non-medicinal ingredients see under DOSAGE FORMS, COMPOSITION AND PACKAGING section of the Product Monograph.

Discontinue the treatment if a skin rash develops after applying the product.

VOLTAREN EMULGEL, VOLTAREN EMULGEL Back & Muscle Pain and VOLTAREN EMULGEL Joint Pain Regular Strength (diclofenac diethylamine gel 1.16% w/w) can be used with non-occlusive bandages but should not be used with an airtight occlusive dressing.

Systemic availability of diclofenac diethylamine through percutaneous absorption is low compared with plasma levels obtained following oral forms of diclofenac. Nevertheless, the possibility of systemic side effects cannot be completely excluded. Chances of this may be increased where Diclofenac diethylamine gel 1.16% w/w is applied to a relatively large area of skin and/or over an extended period of time (*e.g.*, especially if this goes beyond the maximum duration recommended for use).

Some possibility of gastro-intestinal bleeding in patients with a significant history of peptic ulceration has been reported in isolated cases in users of diclofenac diethylamine gel. Diclofenac diethylamine gel 1.16% w/w should therefore be used with caution by patients under medication for active peptic ulcers in the stomach or duodenum (*e.g.*, proton pump inhibitors or histamine H_2 receptor antagonists). If the patient is uncertain, they should be advised to consult their doctor or pharmacist.

Like other drugs that inhibit prostaglandin synthetase activity, diclofenac and other NSAIDs can precipitate bronchospasm if administered to patients suffering from or with a previous history of bronchial asthma.

Asthma has been rarely reported in patients using topical NSAID preparations.

Local irritation, erythema, pruritus or dermatitis may occasionally occur with topical diclofenac diethylamine. Skin photosensitivity, desquamation, discoloration and bullous or vesicular eruptions have been reported in isolated cases. Patients should be warned against excessive exposure to sunlight in order to reduce the incidence of photosensitivity.

The following side effects have been observed with oral forms of diclofenac sodium.

Cardiac and vascular disorders

Uncommon: myocardial infarction, cardiac failure, palpitations, angina, arrhythmias, chest pain Very Rare: hypertension, vasculitis.

Ear and labyrinth disorders

Common: vertigo Very rare: hearing impaired, tinnitus

Eye disorders

Very rare: visual impairment (blurred vision, diplopia)

Gastrointestinal disorders

Very common: nausea, vomiting, diarrhea, abdominal pain, flatulence, decreased appetite. Uncommon: gastritis, gastrointestinal hemorrhage, hemorrhagic diarrhea, melena, hematemesis, gastric and intestinal ulcerations (with or without bleeding or perforation). Vary rare: lower gut disorders (including haemorrhagic colitis and exacerbations of ulcerative colitis or Crohn's disease), intestinal diaphragm diseasehyperacidity, stomatitis, glossitis, coated tongue, oesophageal lesions, constipation, pancreatitis.

Haematologic

Very Rare: thrombocytopenia, leucopenia, agranulocytosis, haemolytic anaemia, aplastic anaemia, anemia secondary to gastrointestinal bleeding.

<u>Hepatic</u>

Common: $elevations(\geq 3 \text{ times the upper normal limit})$ of serum aminotransferase enzymes (SGPT or ALT, SGOT or AST).

Uncommon: liver function disorders including hepatitis, hepatic necrosis, hepatic failure, jaundice.

Very rare: hepatitis fulminant

Immune system disorders

Uncommon: hypersensitivity anaphylactic / anaphylatoid systemic reactions (including hypotension and shock). Very Rare: angioedema (including face edema).

Nervous system disorders

Common: dizziness, headache.

Uncommon: somnolence, malaise, impaired concentration, tiredness. Very Rare: sensory disturbances including paraesthesia, memory impairment, , convulsions, anxiety, tremor, aceptic meningitis, cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage), dysgeusia.

Psychiatric disorders

Very rare: disorientation, depression, insomnia, nightmare, irritability, psychotic disorder.

Renal and urinary disorders

Uncommon: edema (facial, general, peripheral) Very rare: acute kidney injury (acute renal failure), nephrotic syndrome, urinary abnormalities (*e.g.* haematuria and proteinuria), tubulointerstitial nephritis, renal papillary necrosis.

Respiratory disorders

Uncommon: asthma (including dyspnea) Vary rare: pneumonitis

Skin and subcutaneous disorders

Common: rash, pruritus.

Uncommon: Urticaria.

Very Rare: bullous dermatitis, erythema, eczema, erythema multiforme, Stevens-Johnson syndrome, Lyell syndrome (toxic epidermal necrolysis), erythroderma (exfoliative dermatitis), alopecia, photosensitivity reactions, purpura, Henoch-Schonlein purpura.

Information concerning non medicinal ingredients

VOLTAREN EMULGEL, VOLTAREN EMULGEL Back & Muscle Pain and VOLTAREN EMULGEL Joint Pain Regular Strength (diclofenac diethylamine gel 1.16% w/w) contain propylene glycol and fragrance (containing benzyl benzoate) which may cause mild, localised skin irritation in some people. For a complete list of non-medicinal ingredient see under DOSAGE FORMS, COMPOSITION AND PACKAGING.

Special Populations

Pregnant Women/Infertility:

Since no experience has been acquired with diclofenac diethylamine gel in pregnancy, it is not recommended for use in these circumstances.

It is contraindicated during the last trimester of pregnancy, owing to the possibility of uterine inertia, fetal renal impairment with subsequent oligohydramnios and/or premature closure of the ductus arteriosus.

Animal data has shown an increased incidence of dystonia and delayed parturition when drug administration is continued into late pregnancy.

If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible and consult your doctor.

Nursing Women:

It is not known whether topical diclofenac is excreted in breast milk. However, studies in animals detected diclofenac in milk after oral administration.

Diclofenac should only be used during lactation if the expected benefit justifies the potential risk to the newborn. If there are compelling reasons for using it, it should not be applied to the breasts nor should it be used at a higher dosage or for a longer period of time than recommended. Nursing women should consult their doctor before using the product.

Geriatrics (> 65 years of age): No specific hazards are associated with geriatric use of diclofenac diethylamine gel.

Paediatrics (< 16 years of age): Not for use in children under 16 years of age.

Monitoring and Laboratory Tests

No monitoring parameters or laboratory tests are required to monitor response to therapy or possible adverse reactions.

ADVERSE REACTIONS

Adverse Drug Reaction Overview

The adverse event incidence in the clinical studies was very low. The benign safety profile documented in the clinical studies is confirmed in the post-marketing experience in millions of patients worldwide. The adverse events occurring in studies were usually either moderate or mild. Serious adverse events observed in all the studies, conducted over more than a decade, were very few in number and all unrelated to study treatment.

In post-marketing surveillance, approximately 90% of case reports are non-serious. Cutaneous adverse events, occurring mostly at the application site, constitute the most common symptoms reported. Serious adverse events associated with oral forms of diclofenac, including gastrointestinal bleeding, have been reported occasionally. No causal relationship has been established between diclofenac diethylamine gel and these systemic adverse events.

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

The clinical data set includes data obtained in approximately 4926 patients with either the target indication of soft-tissue injuries (*e.g.* sprains, strains, bruises), osteoarthritis or soft-tissue rheumatism, 2728 of whom received VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) 1267 of whom received an active comparator, and 931 of whom received placebo. Patients were treated from 3-28 days as befitted the nature of the conditions under study.

Data from the safety population with the target indication investigated, who received short term exposure to VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) in controlled trials and uncontrolled trials, confirm that a dose of 2-4 g of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) applied topically 3-4 times a day is safe and that the systemic adverse event profile observed for systemic NSAIDs is not seen with the topical formulation.

No subgroup analyses were performed. Long-term safety data from patients was not obtained in these studies as this is not relevant to a product intended for only short-term use up to 1 week. The safety of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) was demonstrated in the safety population in clinical trials, which all showed that the incidence and type of rare or serious events resembles those of active controls or placebo.

The adverse events (AEs) whether or not drug related reported in 33 clinical trials are summarized in Table 1 (WHO-ART coding).

Table 1 - Adverse events (AEs) Reported in Clinical Trials (WHO-ART coding) with a Frequency of $\geq 1\%$

	VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) n= 2258 (100)	<placebo> n= 633 (100)</placebo>	Reference* n= 1112 (100)
Local skin AEs	76 (3.4)	35 (5.5)	29 (2.6)

*Topical reference drugs (number of patients): felbinac (195), piroxicam (306), etofenamate (140), Mobilat containing adrenocortical extract, mucopolysaccharide, salicylic acid (113), Movelat containing mucopolysaccharide polysulphate, salicylic acid (78), ketoprofen (15), naproxen (15), benzydamine HCl (52), indomethacin (55), Dolobene containing dimethylsulfoxid heparin (39), monosalicylic acid (15-20). * Oral reference drug: ibuprofen (155)

Similar percentages of local skin reactions including mostly itching, burning, erythema, local allergy and blistering were reported after VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) (3.4%) and placebo (5.5%). Most of the local AEs were mild to moderate. There were no reports of photosensitivity, although one case report referred to exposure to the sun. Approximately 0.3% of patients were withdrawn due to local skin AEs after applying VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) or placebo.

In conclusion, the absolute numbers of reported adverse events were relatively small and there are no clinically significant differences in the incidence of adverse events in the VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) placebo and reference drug treatment groups. Most of the AEs are local, mild to moderate and reversible.

Less Common Clinical Trial Adverse Drug Reactions (<1%)

WHO-ART-coded clinical trials

Digestive: Dyspepsia was observed in 0.58, 0.32, and 0.18% of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) Placebo, and Reference groups, respectively. Body as a whole: Allergic events were observed in 0.04, 0.16, and 0.09% of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) Placebo, and Reference groups, respectively.

CNS: CNS events were observed in 0.09, 0.32, and 0.45% of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) Placebo, and Reference groups, respectively.

Abnormal Hematologic and Clinical Chemistry Findings

Clinical laboratory evaluations were not routinely performed in the studies undertaken for the indication of muscle and joint soft tissue injuries. The treatments were given for short periods only.

Post-Market Adverse Drug Reactions

Tabulated list of adverse reactions

The table includes adverse reactions from the clinical trials as well as from the post-marketing experience where causal relationship has been established.

Adverse reactions are listed below, by system organ class and frequency. Frequencies are defined as: *very common* ($\geq 1/10$); *common* ($\geq 1/100$ to < 1/10); *uncommon* ($\geq 1/1,000$ to < 1/1,000); *rare* ($\geq 1/10,000$ to < 1/1,000); *very rare* (< 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Infections and infestations

Very rare: Rash pustular

Immune system disorders

Very rare: Hypersensitivity (including urticaria), angioedema

Respiratory, thoracic and mediastinal disorders

Very rare: Asthma

Skin and subcutaneous tissue disorders

Common: Dermatitis (including contact dermatitis), rash, erythema, eczema, pruritus.

Rare: Dermatitis bullous.

Very rare: Photosensitivity reaction

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Canada Vigilance Program.

DRUG INTERACTIONS

Overview

No drug and substance interaction studies have been performed as part of the clinical development of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w).

From the pharmacokinetic point of view, diclofenac is extensively (>99.7%) protein bound, mainly to albumin (99.4%). Binding to serum albumin is characterised by 2 classes of binding sites: the high affinity sites are likely to be shared with benzodiazepines and the low affinity site

with warfarin. Diclofenac does not modify other strongly protein bound drugs but may, *in vitro*, be displaced by salicylic acid (Davies and Anderson, 1997).

There is a considerable body of literature regarding interactions of oral NSAIDs, and diclofenac in particular, with other medicinal products. No interactions with other drugs are to be expected due to very low plasma levels observed after topical application of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w).

Drug-Drug Interactions

No drug-drug interactions were noted in the clinical studies presented. Isolated interaction cases have been reported for topical VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) from the marketplace.

Eighty-six worldwide cases of possible drug interactions with diclofenac diethylamine gel over more than 4 billion patients treatment courses have been entered to the company world-wide safety database since first marketing:

In 64 cases, a possible interaction between diclofenac diethylamine gel and only one other interacting drug was reported:

- Twenty cases with other anti-inflammatory medications (diclofenac, ibuprofen, acetylsalicylic acid, naproxen, piroxicam, celecoxib, and an unknown anti-inflammatory medication); clinical adverse events reported were e.g. pain, arthralgia, somnolence, gastrointestinal haemorrhage, gastric ulcer, haemorrhoids, diarrhoea, renal failure, hypertension, tachycardia, rash).
- Twenty-four cases with oral anticoagulant therapy (acenocoumarol, warfarin, phenprocoumon, fluindione, clopidogrel, and an unknown anticoagulant); only 2 cases did not report any clinical adverse event. The most frequently reported clinical adverse events were haemorrhages (in five cases, e.g. gastrointestinal haemorrhage, epistaxis, gingival bleeding) and international normalized ratio increased (6 cases). Other adverse events reported included renal failure, prothrombin level decreased.
- Six cases with anti-hypertensives (with an unknown anti-hypertensive, candesartan, losartan, lisinopril, captopril, valsartan; clinical adverse events reported were e.g. blood pressure increased, acute kidney injury).
- Three cases of psychiatric disorders (3 cases of confusional state with rivastigmine).
- Five cases with unspecified medications (with clinical adverse events such as dermatitis allergic, skin irritation, renal disorder).
- Two cases of gastrointestinal haemorrhage associated with fluoxetine.
- One case of headache associated with pantoprazole.
- One case of toxicity to lithium associated with lithium.
- One case of erythema and urticaria associated with heat therapy.
- One case of renal disorder associated with torasemide.

In the remaining twenty-two cases, there were more than one possibly interacting medication, with no particular drugs and adverse events pattern identified.

The customary drug-drug interactions between oral NSAIDs and anticoagulants, oral antidiabetic agents and certain other classes are usually based on the high protein-binding nature of the NSAID. With significantly lower amounts of active substance in circulation following topical application compared with after oral administration, such interactions may be predicted to be very unlikely with use of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w).

DOSAGE AND ADMINISTRATION

Recommended Dose and Dosage Adjustment

Adults and adolescents 16 years and older:

- VOLTAREN EMULGEL, VOLTAREN EMULGEL Back & Muscle Pain and VOLTAREN EMULGEL Joint Pain Regular Strength (diclofenac diethylamine gel 1.16% w/w) gel should be applied to the affected area 3 or 4 times daily. It should be rubbed gently into the skin.
- The amount needed depends on the size of the painful area: 2g to 4g (1g equals a strip approx. 2 cm long) of gel is sufficient to treat an area of about 400-800 cm². After application, the hands should be washed.

The duration of treatment depends on the natural course of healing, rest and also on clinical response. The gel should not be used for more than 7 days for muscle and joint injuries, unless recommended by a doctor. Consumers should consult their doctor if the condition does not improve within 7 days, or if it gets worse.

Missed Dose

If a dose of VOLTAREN EMULGEL [or VOLTAREN EMULGEL Back & Muscle Pain or VOLTAREN EMULGEL Joint Pain Regular Strength (diclofenac diethylamine gel 1.16% w/w)] is missed, it should be applied when the consumer remembers and then again at the next scheduled time. A double quantity should not be applied.

OVERDOSAGE

For the management of a suspected drug overdose, contact your regional Poison Control Centre.

The low systemic absorption of topical diclofenac renders overdose very unlikely. However undesirable effects, similar to those observed following an overdose of VOLTAREN tablets, can be expected if VOLTAREN EMULGEL [or VOLTAREN EMULGEL Back & Muscle Pain, or VOLTAREN EMULGEL Joint Pain Regular Strength (diclofenac diethylamine gel 1.16% w/w)] is ingested (1 unit of 100 g contains the equivalent of 1 g diclofenac sodium) respectively. In the event of accidental ingestion, resulting in significant systemic side effects, general therapeutic measures normally adopted to treat poisoning with non-steroidal anti-inflammatory drugs should be used. Further management should be as clinically indicated, or as recommended by the regional Poison Control Centre.

Management of overdosage with NSAIDs essentially consists of supportive and symptomatic measures. Supportive and symptomatic treatment should be given for complications such as hypotension, renal failure, convulsions, gastro-intestinal irritation, and respiratory depression; specific therapies such as forced diuresis, dialysis or haemoperfusion are probably of no help in eliminating NSAIDs due to their high rate of protein binding and extensive metabolism.

Twenty times the oral dose of 200 mg of diclofenac in overdose produced only somnolence with no signs of toxicity (AHFS Drug Information 1999). This would represent about 65 tubes of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w). In case of accidental ingestion of one tube of product, the amount of diclofenac ingested would be less than one tablet of diclofenac 50 mg (which is the most common oral unit dose).

There are 173 worldwide cases of overdose with diclofenac diethylamine in the company safety database. Fifty concern patients of age up to 18 years; 78 concern the adult and elderly population, and 45 concern patients of unspecified age.

In the paediatric population, no adverse event was reported in 39 out of 50 cases; 5 out of 11 cases with clinical adverse events (with patient's age ranging from 5 months to 11 years) reported listed skin reactions after topical application (e.g. rash, urticaria, erythema). Other adverse events reported were burning sensation; skin disorder, alopecia, thermal burn, decreased appetite, thyroid disorder, headache, diarrhoea, nausea, skin reaction, erythema (in this medically confirmed case, the causal relationship with diclofenac diethylamine gel was assessed as unlikely); vomiting, headache and dizziness; inflammation; eye swelling, nasal inflammation and eye inflammation in two children who accidentally received a small amount of gel near the eyes; nausea and feeling abnormal.

There were no cases of accidental ingestion. A 19-month-old child accidentally ran her lips around an opened tube, but no adverse events were reported.

Diclofenac diethylamine gel 1.16% w/w should not be used in adults and adolescents under 16 years.

In the adult population, out of 78 cases, 24 reported clinical adverse events after topical application: e.g. skin reactions (rash, burning sensation, skin exfoliation, eczema, erythema, dermatitis), hypersensitivity symptoms (e.g. swollen tongue, dyspnoea), peripheral swelling, feeling hot, gastrointestinal reactions (e.g. epigastric discomfort in a case with co-suspect celecoxib; abdominal pain upper, vomiting), hypotension (case confounded by concomitant medications), events related to the underlying condition (e.g. pain, arthralgia, chondropathy). A 79-year-old polymedicated patient with a medical history of hypertension, type 2 diabetes mellitus, and respiratory disease developed acute renal failure after using two full tubes of 120

grams in a 10-day period. Angina pectoris occurred in a 46-year-old polymedicated (not further specified) male patient treated with diclofenac free acid for nearly 20 years with a dose of 2 tablets 3 times a day (overdose) in addition to recently started diclofenac diethylamine. A 78-year-old patient treated with fluindione developed haematoma after application of excessive amounts (a tube of 100 ml in 4 days) of diclofenac diethylamine.

In the population of unspecified age, out of 45 cases, only 16 cases reported clinical adverse events after topical application: e.g. skin reactions (e.g. application site pruritus, skin irritation, rash), sensory loss, burning sensation, peripheral swelling, gastritis in a patient with a history of stress-induced gastritis, poisoning (not further specified). In one case, a female patient developed unspecified circulatory system complaints, dizziness and nausea after applying too much product, summarized as misuse of 2 x 150 g per week. Final outcome was complete recovery. A female consumer wanted to commit suicide with diclofenac diethylamine gel (diclofenac diethylamine gel 1.16% w/w); no other adverse event than suicide attempt was reported. In another case, a male patient with an unspecified renal disorder developed comatose state and possible renal failure after use of the product regularly and continuously for more than one year over a large area of skin including the back, the shoulder and the legs. The patient used about 2 tubes every three weeks. In another case, a female patient with alcohol and narcotic addiction used the product to get intoxicated. Diclofenac diethylamine gel was heated, and the vapours were being aspirated with a specific syringe. The content was injected into the mouth or the ear to achieve intoxication from the alcohol that had been extracted from the process. No adverse event other than alcohol poisoning and drug abuse was reported.

There was one case of ingestion: An elderly female patient accidentally swallowed diclofenac diethylamine gel 25g but most of it was not absorbed because the patient spontaneously vomited most of the drug. No further adverse event occurred.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Diclofenac is a well characterized, potent nonsteroidal anti-inflammatory drug (NSAID) with clinically proven anti-inflammatory, analgesic and antipyretic properties (Davies & Anderson 1997). NSAIDs, including diclofenac, reduce pain principally by inhibiting formation of prostaglandins, leukotrienes and free oxygen radicals.

All non-salicylate NSAIDs reversibly block cyclooxygenase activity, which is responsible for converting arachidonic acid to prostaglandins. Diclofenac is a potent, non-selective inhibitor of COX-1 and COX-2 (preferentially COX-2), which may underlie both its therapeutic efficacy and potential side effects (Giuliano & Warner 1999). In addition, diclofenac, when compared to NSAIDs such as ibuprofen, also blocks the lipoxygenase pathway of the arachidonic acid cascade, thereby inhibiting the formation of leukotriene B4 (LTB4), which is a known pain mediator and has been shown to stimulate pain receptors in the peripheral nerves. The inhibition of lipoxygenase also prevents the pro-inflammatory and gastrointestinal damaging effects of leukotrienes (Bertolini, Ottani & Sandrini 2001). Prostaglandins, along with thromboxanes and LTB4, are responsible for several inflammatory effects. The lipoxygenase inhibition produced by diclofenac may therefore play a significant role in its efficacy as an analgesic and anti-inflammatory agent (Amadio, Cummings & Amadio, 1993; Todd & Sorkin 1988).

Pharmacodynamics

Pharmacotherapeutic group: Topical products for joint and muscular pain. Anti- inflammatory preparations, non-steroids for topical use, ATC code: M02A A15.

As with other NSAIDs, the ability of diclofenac to inhibit prostaglandin synthesis is instrumental in the anti-inflammatory response. Data from *in vitro* studies show that most topical NSAIDs are able to inhibit prostaglandin synthesis to a significant degree. In this respect, diclofenac has a high intrinsic activity, as demonstrated *in vitro* in human rheumatoid synovial microsomes (Dreiser 1994).

The pharmacodynamic properties of diclofenac have been demonstrated for each of the sodium, potassium and diethylamine salts administered either orally or topically in standard animal models of acute and chronic inflammation (Hiramatsu *et al* 1990, Kyuki *et al* 1983).

It has also been reported that topically applied diclofenac diethylamine 1.16% actively inhibited methyl nicotinate induced skin inflammation, which is known to involve prostaglandins and free arachidonic acid. Topical diclofenac was shown to exhibit a prolonged potent anti-inflammatory effect, even 48 hours after application (Duteil *et al* 1990).

The anti-inflammatory properties of VOLTAREN EMULGEL(diclofenac diethylamine gel 1.16% w/w) were demonstrated in two placebo-controlled, double-blind, randomized trials, one in healthy volunteers using the urate crystal induced inflammation model (NGB5) and the other in patients with chronic synovitis of the knee (NGB 8855). VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) proved to be superior to placebo in significantly reducing the diameter of erythema at 24 hours in study NGB 5 (p<0.05), and significantly reducing the thermal index in study NGB 8855 (p<0.04). Due to the small size of the studies, only objective parameters of erythema and thermal index could be evidenced.

Pharmacokinetics

Absorption: The quantity of diclofenac absorbed through the skin is proportional to the size of the treated area, and depends on both the total dose applied and the degree of skin hydration. Absorption amounts to about 6% of the applied dose of diclofenac after topical application of 2.5 g VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) on 500 cm² skin, determined by the total renal elimination, compared with Voltaren tablets. A 10-hour occlusion leads to a 3-fold increase in the amount of diclofenac absorbed.

Distribution: Diclofenac concentrations have been measured from plasma, synovial tissue and synovial fluid after topical administration of diclofenac diethylamine gel to hand and knee joints. Maximum plasma concentrations are approximately 100 times lower than after oral administration of the same quantity of diclofenac. 99.7% of diclofenac is bound to serum proteins, mainly albumin (99.4%).

Diclofenac accumulates in the skin which acts as reservoir from where there is a sustained release of drug into underlying tissues. From the skin and underlying tissue, diclofenac

preferentially distributes and persists in deep inflamed tissues (such as the joint), rather than in the bloodstream. Diclofenac is found in tissues at concentrations up to 20 times higher than in plasma.

Metabolism:

Biotransformation of diclofenac involves partly glucuronidation of the intact molecule, and mainly single and multiple hydroxylations, most of which are converted to glucuronide conjugates (hydroxyl-gluconates). The main metabolite is 4-hydroxy-diclofenac (30%-40%). All the metabolites are biologically active, but to a much smaller extent than diclofenac.

Excretion:

The total systemic clearance of diclofenac from plasma is 263 ± 56 ml/min. The terminal plasma half-life is 1-2 hours. Four of the metabolites, including the two active ones, also have short plasma half-lives of 1-3 hours. One metabolite, 3'-hydroxy-4'-methoxy-diclofenac, has a longer half-life but is virtually inactive. Diclofenac and its metabolites are excreted mainly in the urine.

Special Populations and Conditions

There are no gender differences in the pharmacokinetics of diclofenac. No safety or efficacy concerns relating to ethnicity have been identified from the marketplace. Davies and Anderson (1997) discuss the influence of age on diclofenac pharmacokinetics with relevance in the very young and elderly. Also, changes to the skin in the elderly will affect absorption in some patients. However, as plasma levels will be very low after topical application these factors are not a clinical concern. For similar reasons, any effect of hepatic or renal impairment on the pharmacokinetics of diclofenac is unlikely to be clinically significant. In patients with chronic hepatitis or non-decompensated cirrhosis, the kinetics and metabolism of diclofenac are the same as in patients without liver disease (Zimmerer J *et al*, 1982).

STORAGE AND STABILITY

VOLTAREN EMULGEL, VOLTAREN EMULGEL Back & Muscle Pain and VOLTAREN EMULGEL Joint Pain Regular Strength (diclofenac diethylamine gel 1.16% w/w) should be stored between 15 and 30°C.

SPECIAL HANDLING INSTRUCTIONS

There are no special handling instructions for VOLTAREN EMULGEL, VOLTAREN EMULGEL Back & Muscle Pain and VOLTAREN EMULGEL Joint Pain Regular Strength (diclofenac diethylamine gel 1.16% w/w).

DOSAGE FORMS, COMPOSITION AND PACKAGING

VOLTAREN EMULGEL, VOLTAREN EMULGEL Back & Muscle Pain and VOLTAREN EMULGEL Joint Pain Regular Strength are white to practically white, soft, homogenous, creamlike gel and packaged in:

- An aluminium tube with a sealing membrane, coated internally with a phenol-epoxy lacquer. The tube is closed with a polypropylene screw cap, incorporating a point to pierce the aluminium sealing membrane before first use; or
- An aluminium laminated tube [low density polyethylene / aluminium / high density polyethylene (internal layer)] fitted with a high density polyethylene shoulder and closed by a moulded seal. The tube is closed with a polypropylene screw cap, incorporating a moulded feature used to insert, twist and remove the seal before first use.

Pack sizes:

VOLTAREN EMULGEL and VOLTAREN EMULGEL Back & Muscle Pain 20 g, 30 g, 50 g, 100 g, and 150 g tubes.

VOLTAREN EMULGEL Back & Muscle Pain (with no mess applicator) 120 g

VOLTAREN EMULGEL Joint Pain Regular Strength 120 g tubes.

VOLTAREN EMULGEL, VOLTAREN EMULGEL Back & Muscle Pain and VOLTAREN EMULGEL Joint Pain Regular Strength (diclofenac diethylamine gel 1.16% w/w) contain the following nonmedicinal ingredients: Carbomer, cocoyl caprylocaprate, diethylamine, fragrance (containing benzyl benzoate), isopropyl alcohol, liquid paraffin, macrogol cetostearyl ether, propylene glycol, purified water.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION


Drug Substance

Proper name: Diclofenac diethylamine

Chemical name: Diethylammonium {o-[(2,6-dichlorophenyl)-amino]-phenyl} acetate

Molecular formula and molecular mass: C18H22Cl2N2O2, 369.3

Structural formula:



Physicochemical properties: Diclofenac diethylamine is a white to light beige crystalline powder. No polymorphic forms of diclofenac diethylamine have been observed. The solubility of diclofenac diethylamine in water is 15.8 g/L at a pH of 7.8 and a temperature of 18°C, 17.4 g/L at a pH of 7.6 and a temperature of 25°C, and 22.8 g/L at a pH of 7.6 and a temperature of 37°C. Diclofenac diethylamine has a pH range of 6.5-8.3 in a 1% solution in 10% ethanol. Diclofenac diethylamine has a pK_a value of 3.9 ± 0.2 in water at 25°C.

CLINICAL TRIALS

For the indication "pain in muscles and joints injuries", the studies NF 113 and D458 L7/D141 are considered pivotal. Study demographics and trial design for these studies are presented in Table 4.

Study demographics and trial design

Table 4 -	Table 4 - Summary of patient demographics for clinical trials in muscle and joint injuries					
Study #	Trial design	Dosage, route of administration and duration	Study subjects (n=number)	Mean age (Range)	Gender	
NF113	Multicentre, parallel-group, randomised, double-blind, placebo- controlled Subjects had soft tissue trauma resulting in a minor sprain, dislocation, tear of muscle or tendon, or pulled muscle/ contusion	VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) or placebo gel was applied topically 4 times daily at a mean dose of 2.2 g (actual dose was determined by physician)	n=254	VOLTAREN: 34.1 (7-88) Placebo: 35.5 (12-84)	<u>Men</u> VOLTAREN: 72 (57%) Placebo: 83 (65%) <u>Women</u> VOLTAREN: 54 (43%) Placebo: 45 (35%)	
D458 L7/D141	Single-centre parallel-group, randomised double-blind, placebo- controlled Subjects were soldiers with acutely sprained ankles	VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) or placebo gel was applied 3 times daily for up to 14 days	n= 80	VOLTAREN: 22.4 (19-29) Placebo: 22.2 (19-31)	All 80 subjects were male	

Study results - Soft tissue trauma

Study NF113

There was a significant difference in favour of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) for spontaneous pain on deliberate movement on day 7 with 44% (51) of the active treatment group having no pain, 43% (50) having only moderate pain and 13% (15) marked pain compared with 35% (41), 38% (44) and 24% (28) of the subjects in the placebo group respectively. Three (3) subjects (3%) of the placebo group had very marked pain at 7 days whereas no active treatment subject had marked pain (p=0.05 for day 7 evaluation) and similar results were found for pain on pressing, also on day 7 (p=0.02). The need for rescue medication was lower in the active treatment group, and of significantly shorter duration *i.e.*, those in the active treatment group stopped using rescue medication before those receiving placebo (p=0.02). The regression of haematoma was also faster in the active treatment group (p=0.04). These data concur with the investigator's general assessments rating the results on day 7 as 'excellent' in 64% of patients receiving active treatment and 52% in those receiving placebo.

Study D458 L7/D141

There was a significant difference for articular pain at rest and on movement (100 mm VAS) and joint swelling at days 3 and 4 in the VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) treated group compared to the placebo group (p<0.001). (The mean pain at rest (mornings) fell from 61.15 on the VAS to 24.13 by day 4 for the active treatment group compared to a fall from 53.33 at baseline to 29.71 on day 4 for the placebo treated group-p<0.001.) Patients withdrew as they got better and so by the 7th day, only those who had not yet healed still remained in the study. At this point there was no difference between active and placebo for joint swelling. Similar numbers of patients in each group required rescue analgesia. 60% of actively treated patients were able to stop using the gel before the 14th day as they were free of symptoms compared with 38% of the placebo group. Interruptions for inadequate efficacy occurred in the placebo group only (2 subjects). During the first 10 days of treatment, nearly twice as many active treatment patients became free of symptoms than the placebo treated group (n=17 and n=8 respectively, p value not given in final study report). This gives an indication of the effect of treatment on the natural time course for pain relief.

DETAILED PHARMACOLOGY

Systemic absorption of diclofenac following topical application of diclofenac diethylamine gel is about 6% of the administered dose and the peak plasma levels attained are 50 times (repeated doses) to 100 times (single dose) lower than those observed after an oral dose. Supportive of efficacy is adequate tissue concentrations of diclofenac in the targeted area after topical application. Overall, diclofenac diethylamine gel can be expected to produce a direct anti-inflammatory and analgesic effect with significantly less AEs than after the oral administration of diclofenac.

Pharmacokinetics

Evidence in humans and animals with topical NSAIDs, including diclofenac, demonstrates lower plasma concentrations than with systemically administered NSAIDs, while drug concentrations in the soft tissues around the area of application are still of a magnitude considered sufficient to exert an anti-inflammatory response. Reviews of the therapeutic effectiveness and PK of diclofenac include Chlud & Wagener (1987, 1991), Chlud (1999), Grahame (1995), Davies & Anderson (1997), and Vaile & Davies (1998).

Percutaneous Absorption, Distribution, Metabolism, Excretion

Absorption of various NSAIDs, including diclofenac, occurs to a depth of at least 3-4 mm through the underlying dermis and subcutaneous tissue (Singh & Roberts 1994). At that level, uptake of drug from the dermal microcirculation into the systemic circulation occurs but the concentration of drug in these layers is always higher than the plasma concentration. Although only a small proportion of the dose is absorbed, the skin acts as reservoir from which there is a sustained release of drug into underlying tissues (Dreiser 1994, Sioufi *et al* 1994). The concentration of the drug is higher in the dermis and subcutaneous tissue below the application site than at greater depths where the drug concentration becomes less than the corresponding plasma concentration. Thus, anti-inflammatory effects at deeper tissue levels may be influenced by both direct and systemic drug concentrations (Singh & Roberts 1994).

A recent multiple-dose, 7 day PK study (VOPO-PE-102) was conducted with VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) and VOLTAREN EMULGEL Extra Strength (diclofenac diethylamine gel 2.32% w/w). On day 1, mean diclofenac plasma concentrations from the two topical treatments did not exceed the LLOQ (0.5 ng/mL) until at least 14 hours after the first dose, and steadily increased to 2-3 ng/ml after 24 hours. The reservoir function is important during the first day after application where the concentration of diclofenac in the stratum corneum is highest (Schaefer and Redelmeier 1996).

Mean trough values were similar over days 5 through 7, indicating that steady state was reached by Day 5 with mean diclofenac plasma concentrations of roughly 3 ng/ml. On Day 7, the mean plasma concentrations were low and the peak-to-trough fluctuation was modest. In contrast, after oral dosing, Day 7 mean plasma concentrations increased sharply and returned approximately to pre-dose levels within the 6-hour dose interval.

The data can be described by a linear one-compartment model with the absorption as the rate limiting factor, (i.e. flip-flop kinetics when absorption is considerably slower than disposition) which is often seen with topical formulations due to the persistence of the compound in the skin reservoir.

The concentration of the drug is higher in the dermis and subcutaneous tissue below the application site than at greater depths where the drug concentration becomes less than the corresponding plasma concentration. Thus, anti-inflammatory effects at deeper tissue levels may be influenced by both direct and systemic drug concentrations (Singh & Roberts 1994).

When diclofenac diethylamine gel is applied topically, the amount of diclofenac absorbed through intact skin is proportional to the contact time and skin area covered and depends on the total topical dose and the hydration of the skin.

Systemic absorption amounts to approximately 3-7% of the dose of diclofenac after topical application of 2.5g VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) per 500 cm² skin, left for 12 hours on non-occluded skin (Riess *et al* 1986, Davies & Anderson 1997). Plasma drug concentrations are well below those observed after a standard oral or intramuscular dose and below the range at which systemic AEs usually occur. Maximum plasma concentrations of diclofenac after topical administration of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) are between 50 (repeated dose) and 100 (single dose) times lower than after oral administration of VOLTAREN tablets (Riess *et al* 1986). The steady state is reached after 2 days of twice-daily administration and the low plasma levels remain in the same range over the full day indicating prolonged absorption from the application site (Sioufi *et al* 1994). Absorption of diclofenac through the skin can be increased by 3-10 times after application of an occlusive dressing.

Report 17727B-510.20-02-01-B describes a single and multiple dose (7 days), open, randomized, three-way cross-over, comparative bioavailability trial of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w), diclofenac enteric coated tablet and a diclofenac patch formulation that was in development in the Company, in 24 healthy volunteers. The main pharmacokinetic findings are summarized in Table 5.

Table 5 - Summary of pharmacokinetic data for Study NCH 17727B-510.20-02-01B					
Parameter	Voltaren Emulgel (diclofenac	VOLTAREN tablet			
	diethylamine gel 1.16% w/w)	25 mg t.i.d			
	4g (40 mg diclofenac-Na				
	equivalent) t.i.d				
<u>After first administratio</u>	<u>n (day 1)</u>				
C _{max} (ng/ml)	5.36 (0.502 - 42.6)	370 (92.0 - 984)			
$t_{max}(h)$	20.00 (10.00 - 23.95)	4.00 (1.00 - 18.00)			
AUC ₀₋₂₄ (ng.h/ml)	43.6 (0.502 - 240)	1190 (231 - 3800)			
After last morning admi	<u>nistration (day 7)</u>				
C _{max} (ng/ml)	12.0 (2.54 - 45.1)	380 (51.0 - 1330)			
$t_{max}(h)$	18.00 (0.00 - 20.00)	4.00 (1.00 - 20.00)			
AUC ₀₋₂₄ (ng.h/ml)	179 (51.8 - 332)	1360 (327 - 4690)			
C _{min} (ng/ml)	4.07 (1.19 - 8.06)	2.11 (<0.5 - 4.79)			
PTF (%)	95.0 (36.2 - 313)	664 (360 - 1250)			

As expected, these data demonstrate that the relative bioavailability of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) *versus* tablets remained low ($C_{max} < 2\%$ and 3% and AUC 4% and 13% respectively) after first and last administration.

Diclofenac is extensively protein bound in plasma (>99.7%), mainly to albumin (99.4%) (Reiss *et al* 1978). The liver is the primary site of metabolism for diclofenac (Davies & Anderson 1997) to virtually inactive metabolites (Stierlin, Faigle & Colombi 1978, Stierlin *et al* 1979,

Faigle *et al* 1988). The total systemic clearance of diclofenac from plasma is 263 ± 56 ml/min (mean value \pm SD). The terminal plasma half-life is 1 to 2 hours. Diclofenac and its metabolites are excreted mainly in urine (60%).

Diclofenac in target tissues

After topical administration of diclofenac diethylamine gel to hand and knee joints in patients, diclofenac can be measured in the synovial tissue and synovial fluid with concentrations as high as 20 times the plasma concentration (Riess *et al* 1986). In study C.R.B. R8/1986 plasma concentrations of diclofenac recorded on the fourth day in 7 patients ranged from 6 to 52 ng/ml with one extreme value of 698 ng/ml. In synovial fluid, the concentrations of diclofenac ranged from 119 to larger than 3320 ng/ml and in synovial tissue ranged from 131 to 1740 ng/ml. In the other patient study T13/1987 diclofenac could not be detected in plasma samples. In synovial fluid from knee joints the diclofenac concentrations were in the range of 6.5-22.1 ng/g sample. These patient studies confirm that topically applied diclofenac will reach the target tissues (soft tissue/joint) at sufficient concentrations to exert a therapeutic response. Relevant publications include Radermacher *et al* (1991), Gondolph-Zink & Gronwald (1996), Day *et al* (1999), Kurowski & Dunky (1992), Chlud & Wagener (1987, 1991), Chlud (1999), Dreiser (1994), and Giuliano & Warner (1999).

Drug and substance interactions

The customary drug-drug interactions between oral NSAIDs and anticoagulants and oral antidiabetic agents, for example, are usually consequent to the high protein-binding of the NSAID. With a significantly lower amount of active substance in circulation following topical application than after oral administration, such interactions may be predicted to be very unlikely with diclofenac diethylamine gel.

Pharmacokinetics in special patient populations

There are no gender differences in the pharmacokinetics of diclofenac. No safety or efficacy concerns relating to ethnicity have been identified from the marketplace. Davies and Anderson (1997) discuss the influence of age on diclofenac pharmacokinetics with relevance in the very young and elderly. Also, changes to the skin in the elderly will affect absorption in some patients. However, as plasma levels will be very low after topical application these factors are not a clinical concern. For similar reasons, any effect of hepatic or renal impairment on the pharmacokinetics of diclofenac is unlikely to be clinically significant. In patients with chronic hepatitis or non-decompensated cirrhosis, the kinetics and metabolism of diclofenac are the same as in patients without liver disease (Zimmerer J *et al*, 1982).

Pharmacodynamics

Pharmacodynamics studies - anti-inflammatory activity

As with other NSAIDs, the ability of diclofenac to inhibit prostaglandin synthesis is instrumental in the anti-inflammatory response. Data from *in vitro* studies show that most topical NSAIDs are able to inhibit prostaglandin synthesis to a significant degree. In this respect, diclofenac has a

high intrinsic activity, as demonstrated *in vitro* in human rheumatoid synovial microsomes (Dreiser 1994).

Prostaglandins, along with thromboxanes and leukotriene B4 (LTB4), are responsible for several inflammatory effects such as vasodilatation, increased vascular permeability, hyperalgesia and increased platelet aggregation. Free oxygen radicals, also mediators of inflammation, are by-products of prostaglandin synthesis. Diclofenac non-specifically inhibits the cyclo-oxygenase pathway with a subsequent reduction in prostaglandin, prostacyclin and thromboxane production. Although non specific, diclofenac inhibits preferentially COX-2 pathway (Giuliano & Warner 1999). The production of leukotrienes is also decreased following the administration of diclofenac, suggesting an inhibitory effect on the lipoxygenase pathway with direct impact on LTB4 and inhibition of pain (Amadio, Cummings & Amadio 1993).

The pharmacodynamic properties of diclofenac have been demonstrated for each of the sodium, potassium and diethylamine salts administered either orally or topically in standard animal models of acute and chronic inflammation (Hiramatsu *et al* 1990, Kyuki *et al* 1983).

It has also been reported that topically applied diclofenac diethylamine 1.16% w/w actively inhibited methyl nicotinate induced skin inflammation, which is known to involve prostaglandins and free arachidonic acid. Topical diclofenac was shown to exhibit a prolonged potent anti-inflammatory effect, even 48 hours after application (Duteil *et al* 1990).

The anti-inflammatory properties of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) were demonstrated in two placebo-controlled, double-blind, randomized trials (refer to Table 6), one in healthy volunteers using the urate crystal induced inflammation model (NGB5) and the other in patients with chronic synovitis of the knee (NGB 8855). VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) proved to be superior to placebo in significantly reducing the diameter of erythema at 24 hours in study NGB 5 (p<0.05), and significantly reducing the thermal index in study NGB 8855 (p<0.04). Due to the small size of the studies, only objective parameters of erythema and thermal index could be evidenced.

Table 6 - Sun	Table 6 - Summary of Studies NGB 5 and NGB 8855					
Study Investigator Country	Regimen Design Comparator	Condition	Population	Criteria	Efficacy	
NGB 5 P.A. Dieppe UK	5 applications in 48 hours (every 12 hr) DB, CO Placebo	Urate crystal induced inflammation Model	Total: 19 (healthy volunteers) Age range: 18-50 years	Lesion diameter, tenderness, intensity of erythema, subject and investigator preference.	VE vs. Placebo: significantly reduced erythema diameter at 24 hours. Investigator's and volunteer's preference at 48 hours (p<0.05).	
NGB 8855 B. Hazelman UK	3/day up to 7 days DB, CO Placebo	Mild to moderate chronic synovitis of knee	Total: 13 Male: 38% Mean age: 55 years Age range: 13-82 years	Thermal index, tenderness, pain on passive movement, swelling, rescue medication.	VE vs. Placebo: reduced thermal index (p<0.04).	

Duteil, *et al* (1990) compared the potency of VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) with that of five other topical NSAIDs (indomethacin, ibuprofen, phenylbutazone, bufexamac and niflumic acid) and three topical corticosteroids (clobetasol, hydrocortisone and hydrocortisone butyrate) in healthy volunteers. Four hours after a single application of each drug to the forearm, inhibition of methyl-nicotinate induced inflammation was greatest with VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) and indomethacin cream (84% and 85%, respectively, relative to a control vehicle). VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) demonstrated the most sustained anti-inflammatory effect, providing 75% inhibition when re-tested 48 hours after application.

Pharmacodynamics studies - analgesic activity

Interestingly, diclofenac also blocks the lipoxygenase pathway of the arachidonic cascade, thereby inhibiting the formation of LTB4 which is known to be a pain mediator stimulating the pain receptors in the peripheral sensory nerves (Martin, *et al* 1988). Inhibition of lipoxygenase also decreases the formation of the slow-reacting substance of anaphylaxis (composed of leukotriene C4, D4 and E4).

In animals, using the Randall and Sellito's test, VOLTAREN EMULGEL (diclofenac diethylamine gel 1.16% w/w) has been shown to increase the pain threshold after a single subcutaneous injection of yeast suspension (Kyuki *et al* 1983).

TOXICOLOGY

The toxicology of VOLTAREN EMULGEL 11.6 mg/g (Diclofenac diethylamine gel (1.16% w/w) was investigated in a series of *in vivo* studies, including acute and three-month repeat dose toxicity, but concentrating particularly on potential local tolerance and photo-safety issues, as outlined in Table 7 below.

Study type and duration	Route of administration	Species	Compound administered
Single-dose toxicity	Topical, occluded	Rat	VOLTAREN EMULGEL 11.6 mg/g
Single-dose toxicity	Oral	Rat	(Diclofenac diethylamine gel (1.16% w/w)
Repeat-dose toxicity: 3 months	Topical, occluded	Rabbit	VOLTAREN EMULGEL 11.6 mg/g (Diclofenac diethylamine gel 1.16% w/w)
Local tolerance / photo-saf	ety		
Phototoxicity, single dose	Topical	Mouse	VOLTAREN EMULGEL 11.6 mg/g (Diclofenac diethylamine gel 1.16% w/w)
Phototoxicity, single dose	Topical	Guinea pig	VOLTAREN EMULGEL 11.6 mg/g (Diclofenac diethylamine gel 1.16% w/w)
Photo-allergenicity	Topical	Guinea pig	VOLTAREN EMULGEL 11.6 mg/g (Diclofenac diethylamine gel 1.16% w/w)
Skin sensitization	Topical, occluded	Guinea pig	VOLTAREN EMULGEL 11.6 mg/g (Diclofenac diethylamine gel 1.16% w/w)
Skin irritation, 5 days	Topical, occluded	Rabbit	VOLTAREN EMULGEL 11.6 mg/g (Diclofenac diethylamine gel 1.16% w/w)
Skin irritation, 5 days	Topical, occluded	Rabbit	VOLTAREN EMULGEL 11.6 mg/g (Diclofenac diethylamine gel 1.16% w/w)
Eye irritation, single dose	Ocular	Rabbit	VOLTAREN EMULGEL 11.6 mg/g (Diclofenac diethylamine gel 1.16% w/w)

VOLTAREN EMULGEL (diclofenac diethylamine gel 11.6 mg/g/ 1.16% w/w) gel was generally well tolerated. The acute toxicity of diclofenac diethylamine was essentially the same as that of diclofenac sodium when expressed in terms of the base. There was no evidence of any significant local irritancy, unexpected toxicity or of any photo-safety concerns.

There have been no other studies specifically designed to investigate toxicity of the drug substance, diclofenac diethylamine, or of the drug product, VOLTAREN EMULGEL (diclofenac diethylamine gel 11.6 mg/g/ 1.16% w/w). The non-clinical toxicology of diclofenac sodium is directly relevant to diclofenac diethylamine and is summarized below.

Single dose experiments in mice, rats, rabbits and dogs indicate an acute intravenous LD_{50} in the region of 100 mg/kg and an oral LD_{50} nearer 200 mg/kg with little evidence to suggest any significant influence of age or sex on the outcome. An oral study in baboons suggests significantly greater tolerance with a probable LD_{50} of more than 600 mg/kg. Death following intravenous administration was usually attributed to respiratory or cardiac failure, those following oral administration to gastrointestinal problems.

Repeat dose oral gavage studies of up to 6 months duration in rats indicate a no observed adverse effect level (NOAEL) of 1 to 2 mg/kg/day. A similar result was obtained in a one-month mouse study by dietary administration. At doses greater than 4 mg/kg/day, deaths were common and usually associated with mild anaemia, neutrophilia, disturbance of plasma proteins, increased extramedullary haematopoiesis and, most prominently, ulceration of the gastrointestinal tract with accompanying peritonitis. These latter were commonly associated with hypertrophy or reactive hyperplasia of the mesenteric lymph nodes.

In a series of baboon studies, similar changes were apparent with deaths consistently seen within 3 months of treatment at 20 mg/kg/day or more. In a 1-year study, 5 of 14 animals treated at 15 mg/kg/day had died by 8.5 months when this dosage was reduced to 10 mg/kg/day. Both constipation and diarrhoea were apparent and there was a high incidence of skin ulcers the severity of which was treatment-related. In both three-month studies, but not in the one-year study, there was evidence of nephropathy at the high dose with increased blood urea nitrogen and disturbance of plasma electrolytes in one study. In the one-year study only and at the high dose only (where 13 of 14 animals died despite a dosage reduction) adrenal cortical hyperplasia was noted in several animals. Other changes seen in baboons were essentially similar to those in rats and the deaths were all associated with gastrointestinal changes. Gastrointestinal changes were seen at the lowest dosages studied in baboons (around 3-5 mg/kg/day) but were generally considered to reflect an exacerbation of pre-existing conditions rather than a primary effect of treatment with diclofenac.

The potential genetic toxicology of diclofenac sodium has been studied in a wide variety of *in vitro* and *in vivo* studies. Most of these studies were carried out many years ago and include:

- Ames tests of the drug, of urine and bile concentrates, and of the major hydroxy-metabolites of diclofenac.
- *In vitro* mammalian cell mutation studies of diclofenac sodium and its hydroxy-metabolites.
- *In vivo* chromosome aberration and nucleus anomaly tests in Chinese hamsters after both short-term treatment and repeated administration for 12 weeks.
- Metaphase analyses of spermatogonia and spermatocytes following five administrations.
- A dominant lethal study in mice.

None of these studies gave any indication of a positive outcome. Recently fully GLP compliant *in vitro* photo-mutagenicity and photo-chromosome aberration studies have been carried out. The photo-mutagenicity study (Ames test) was also negative. Chromosome aberrations were seen in the other study at 25 μ g/ml and with 16 minutes of UV radiation. These conditions were associated with a reduced mitotic index and the apparently positive result is attributed to

cytotoxicity. No chromosome aberrations were seen at lower doses of UV or at lower concentrations of diclofenac. An additional conventional *in vivo* GLP compliant chromosome aberration study has also been completed with diclofenac sodium and was also negative.

One mouse and two rat carcinogenicity studies have been conducted. Exposure levels, as judged from plasma concentration data obtained during the more recent of these studies, were 12-45 ng/g in mice at the NOAEL (0.3 mg/kg/day) and 10-48 ng/ml in rats at the lowest dosage (0.25 mg/kg/day). In all 3 studies there was a dosage-related increase in mortality at 1 and 2 mg/kg/day with only isolated animals surviving at the high dose. Most deaths were associated with gastrointestinal ulceration and peritonitis. There were few changes that could be ascribed to treatment at lower dosages (0.1 to 0.5 mg/kg/day) and there was no treatment-related increase in the incidences of benign or malignant tumours in any of these studies.

Reproduction toxicity has been assessed in a series of pre-ICH design studies, including Segment I and III studies in rats and a variety of Segment II studies in mice, rats and rabbits. Almost all studies included treatment at toxic dosages and death of the dams, usually attributed to peritonitis, was a common finding. Treatment with diclofenac sodium in the Segment I and III studies was generally associated with a slight increase in gestation and occasional dystocia resulting in increased peri-natal mortality. Even discounting this, there was usually an increase in embryo-foetal and/or perinatal losses. Birth weight was reduced. Foetal changes extended to the lowest dosage examined, 2 mg/kg/day, in both studies. Other than deaths associated with dystocia, post-natal survival was not affected.

In the Segment II studies in mice, there was no clear effect of treatment at 2 or 4 mg/kg/day when given orally, even when administered through days 0-17 of gestation. Reductions in foetal numbers and reduced ossification at higher dosages were associated with severe maternal toxicity. In oral rat studies a similar picture emerged. There were some minor contradictory findings at 4 mg/kg/day but none at 2 mg/kg/day and clear effects at higher dosages, including reduced ossification, that were attributed to maternal toxicity. An intramuscular study indicated no changes in the foetuses at 10 mg/kg/day, despite maternal sedation and local injection site responses. In a GLP compliant subcutaneous rat study, however, minimally reduced ossification was identified at 1.2 mg/kg/day; 0.4 mg/kg/day was a NOAEL. In an oral rabbit Segment II study, 5 mg/kg/day was a clear NOAEL, changes at 10 mg/kg/day included increased embryonic and foetal resorptions and reduced foetal ossification in three foetuses. An intramuscular rabbit study identified 3 mg/kg/day as the NOAEL with increased abortions and dead foetuses, reduced number of fully formed foetuses and reduced ossification, and reduced foetal viability at higher dosages, associated with maternal toxicity.

REFERENCES

American Hospital Formulary Service. AHFS Drug Information; 1671, 1679-84, 1700, 1705, 1715, 1718-9, 1731, 1736, 1826, 1828-9. American Society of Health System Pharmacists (1999). The most comprehensive authoritative source of evaluative drug information.

Amadio P, Cummings DM and Amadio P (1993) Nonsteroidal anti-inflammatory drugs. Tailoring therapy to achieve results and avoid toxicity. Postgrad Med; 93(4): 73-6, 79-81, 85-6, 88, 93-6.

Bertolini A, Ottani A and Sandrini M (2001) Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol Res; 44(6): 437-50.

Chlud K, Wagener HH (1987) Perkutane Therapie mit NSAID (Non-steroidal Anti-Inflammatory Drugs) unter besonderer Berücksichtigung kinetischer Fragen. EULAR Bull; 2: 41-45.

Chlud K and Wagener HH (1991) Perkutane Therapie mit nichtsteroidalen Antiphlogistika. Fortschr Med; 109(2): 29-32.

Chlud K (1999) Zur Anwendung von NSAR-Topika bei irritierten und dekompensierten Arthrosen. Wien Med Wochenschr; 149: 546-7.

Davies NM, Anderson KE (1997) Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet; 3(3):184-213.

Day RO, McLachlan AJ, Graham GG, *et al* (1999) Pharmacokinetics of nonsteroidal antiinflammatory drugs in synovial fluid. Clin Pharmacokinet; 36(3): 191-210.

Dreiser RL (1994) Topical antirheumatic drug therapy: current practice and future trends. Eur J Rheumatol Inflamm; 14(4): 3-8.

Duteil L, Queille C, Poncet M, *et al* (1990) Objective assessment of topical corticosteroids and non-steroidal anti-inflammatory drugs in methyl-nicotinate-induced skin inflammation. Clin Exp Dermatol; 15: 195-9.

Faigle JW, Böttcher I, Godbillon J, *et al* (1988) A new metabolite of diclofenac sodium in human plasma. Xenobiotica; 18(10): 1191-7.

Giuliano F and Warner TD (1999) *Ex Vivo* assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs. Br J Pharmacol; 126: 1824-30.

Gondolph-Zink B, Gronwald U (1996) Wirkstoffkonzentrationen in artikulären und periartikulären Geweben des Kniegelenkes nach kutaner Anwendung von Diclofenac-Diethylammonium Emulgel. Akt Rheumatol; 21: 298-304. Grahame R (1995) Transdermal non-steroidal anti-inflammatory agents. Br J Clin Pract; 49 (1): 33-35.

Hiramatsu Y, Akita S, Salamin PA, *et al* (1990) Assessment of topical non-steroidal antiinflammatory drugs in animal models. Arzneim. Forsch; 40: 1117-1124.

Kurowski M, Dunky A (1992) Transdermal absorption of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis patients; I. diclofenac. Int J Pharm Ther Toxicol; 30(11): 479.

Kyuki K, Shibuya T, Tsurumi K, *et al* (1983) Anti-inflammatory effect of diclofenac sodium ointment (cream) in topical application. Japan J Pharmacol; 33: 121-132.

Martin H, Basbaum A, Goetzl J, *et al* (1988) Leukotriene B4 Decreases the Mechanical and Thermal Thresholds of C-Fiber Nociceptors in the Hairy Skin of the Rat. Journal of Neurophysiology; 60: 438-445.

Radermacher J, Jentsch D, Scholl MA, *et al* (1991) Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. Br J Clin Pharmacol; 31: 537-41.

Riess W, Schmid K, Botta L, *et al* (1986) Percutaneous absorption of diclofenac. Arzneim Forsch; 36 (2): 1092-1096.

Singh P, Roberts MS (1994) Skin permeability and local tissue concentrations of non-steroidal anti-inflammatory drugs after topical application. J Pharm Exp Ther; 268: 144-151.

Sioufi A, Pommier F, Boschet F, *et al* (1994) Percutaneous absorption of diclofenac in healthy volunteers after single and repeated application of diclofenac emulgel. Biopharm Drug Disp; 15: 441-449.

Stierlin H, Faigle JW, Colombi A (1978) Pharmacokinetics of diclofenac sodium (VOLTAREN) and metabolites in patients with impaired renal function. Scand J Rheumatol; Suppl 22: 30-5.

Stierlin H, Faigle JW, Sallmann A, *et al* (1979) Biotransformation of diclofenac sodium (VOLTAREN) in animals and in man. Isolation and identification of principal metabolites. Xenobiotica; 9(10): 601-10.

Todd PA and Sorkin EM (1988) Diclofenac sodium: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs; 35:244-85.

Vaile JH, Davis P (1998) Topical NSAIDs for musculoskeletal conditions. A review of the literature. Drugs; 56 (5): 783-799.

Zimmerer J et al. (1982) Rheuma-Therapie bei Leberkranken. Fortschr Med; 36:1683-1688.

PART III: CONSUMER INFORMATION

Voltaren Emulgel

Diclofenac diethylamine gel 11.6 mg/g (1.16% w/w)

This leaflet is part III of a three-part "Product Monograph" published when **Voltaren Emulgel** was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about **Voltaren Emulgel**.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- Contact your doctor or pharmacist if you have any questions about the drug or need more information or advice.

Separate Product Monograph available for VOLTAREN EMULGEL Extra Strength and VOLTAREN EMULGEL Joint Pain Extra Strength (Diclofenac diethylamine Gel, 23.2 mg/g /2.32% w/w)

ABOUT THIS MEDICATION

What the medication is used for:

Voltaren Emulgel

• For the relief pain associated with recent (acute), localized minor muscle or joint injuries such as sprains, strains or sports injuries (e.g. sprain of ankle, strain of shoulder or back muscles). This is typically as an adjunct to other measures such as rest for the relief of discomfort associated with such injuries

What it does:

Voltaren Emulgel is specially formulated for rubbing into the skin to relieve acute pain affecting the joints and muscles. The active substance, diclofenac, is one of the groups of medicines called non-steroidal antiinflammatory drugs (NSAIDs) that work within the body by blocking the production of particular substances, called prostaglandins, which are involved in the development of pain and inflammation.

When it should not be used:

- If you are currently taking diclofenac or any other over-the-counter or prescription oral non-steroidal anti-inflammatory drug (NSAID) which are used to treat pain, fever or inflammation, such as ibuprofen, acetylsalicylic acid (ASA) or naproxen. If you are not sure, ask your doctor or pharmacist.
- If in the past you have had allergic reactions to diclofenac or any other NSAIDs such as ibuprofen, ASA or naproxen.
- If you have attacks of asthma, urticaria (hives), or acute rhinitis (nasal inflammation, irritation or stuffy nose that lasts less than 6 weeks), swelling of the face or tongue, runny nose after taking ASA or other NSAIDs
- If you are allergic to any of the nonmedicinal ingredients in the gel (see list of nonmedicinal ingredients).
- If you are in the last 3 months of pregnancy as it could harm your unborn child or cause problems at delivery.
- Do not use right before or after heart surgery.

If any of these applies to you, do not use this medicine. If you are not sure, ask your doctor or pharmacist.

What the medicinal ingredient is:

Diclofenac diethylamine

What the nonmedicinal ingredients are:

Voltaren Emulgel 1.16% w/w gel contains the following nonmedicinal ingredients: Carbomer, cocoyl caprylocaprate, diethylamine, fragrance (containing benzyl benzoate), isopropyl alcohol, liquid paraffin, macrogol cetostearyl ether, propylene glycol, purified water.

Propylene glycol and benzyl benzoate may cause mild localized skin irritation in some people.

What dosage forms it comes in:

Voltaren Emulgel 1.16% w/w gel come in tubes of 20 g, 30 g, 50 g, 100 g and 150 g.

The gel is white to practically white, cooling, nongreasy, non-staining, cream-like.

WARNINGS AND PRECAUTIONS

BEFORE you use **Voltaren Emulgel** talk to your doctor or pharmacist if:

- You have a history of stomach ulcers or take medication for such gastrointestinal disorders.
- You are pregnant, or think you may be pregnant, or are planning to have a baby or are breast feeding.
- You are taking, or have recently taken, any other medicines, including Over the Counter drugs.

PROPER USE OF THIS MEDICATION

Voltaren Emulgel is not<u>intended</u> for use in children under the age of 16.

Do not apply to cuts or open wounds or to skin that has a rash or eczema. Discontinue the treatment if a skin rash develops after applying the product.

Avoid applying on large areas of skin or for a longer than approved duration of use, unless under medical advice.

A brace or wrap commonly used for injuries like sprains can be used but do not wrap the skin with an airtight (plastic) or occlusive dressing when using **Voltaren Emulgel**.

In very rare cases, your skin may be more sensitive to sunlight while using this product. Use caution during sun exposure or when using tanning booths/sun lamps. Possible signs are sunburn with itching, swelling and blistering.

Be careful not to get it in your eyes. If this happens, rinse your eyes well with clean water and tell a doctor or a pharmacist.

Voltaren Emulgel is for EXTERNAL USE ONLY.

Do not use it in the mouth, vaginal or anal areas.

Never swallow it.

INTERACTIONS WITH THIS MEDICATION

Check with your doctor or pharmacist if you are taking any other NSAIDs (e.g. ibuprofen, acetylsalicylic acid or naproxen) or anticoagulants (blood thinners), high blood pressure medication, oral anti-diabetic agents, fluoroquinolone antibiotics (*i.e.*, ofloxacin) or are taking medication for peptic ulcers, gastroesophageal disease or to control excess acidity. If you suspect a drug interaction, notify your doctor or pharmacist.

Usual dose:

Voltaren Emulgel:

For adults and adolescents 16 years and older:

- Apply gel 3 to 4 times a day.
- The amount needed will vary depending upon the size of the painful or swollen area: 2 g to 4 g (1 g equals a strip approximately 2 cm long) gel will be sufficient to cover a 400 to 800 cm² area. Do not use more than 4 times in 24 hours.
- Tubes: before first use, unscrew and remove the cap. Use the reverse side of the cap to insert, twist and remove the seal from the tube (see figure 1)
- Figure 1:



- Tubes: gently squeeze out a small amount of gel from the tube and apply to the painful or swollen area, slowly rubbing into the skin. You may notice a slight cooling effect when you rub the gel in.
- Wash your hands after rubbing in **Voltaren Emulgel**, to avoid accidental contact with the mouth and eyes.

The gel should not be used for more than 7 days for muscle and joint injuries unless recommended by a doctor. Talk to your doctor if your condition does not improve within 7 days, or if it gets worse.

Overdose:

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

If you dispense more gel than needed, wipe off the surplus gel with a tissue.

If you or a child accidentally swallows the gel, contact your doctor immediately.

Missed Dose:

If you miss applying **Voltaren Emulgel** at the correct time, apply it when you remember and then next apply it at the usual time. Do not apply a double quantity.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Itching, reddening or slight irritation of the skin are common after use of **Voltaren Emulgel**. These symptoms are usually mild, passing and harmless. If you are concerned, tell a doctor or pharmacist. Discontinue the treatment if a skin rash develops after applying the product.

SERIOUS SIDE EFFECTS, HOW OFTEN
THEY HAPPEN AND WHAT TO DO ABOUT
THEM

Symptom / effect	Talk with your doctor or pharmaci	Stop taking drug and call your
	st	doctor or
		pharmacis
		t

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom /	effect	Talk with your doctor or pharmaci st	Stop taking drug and call your doctor or pharmacis t
Some rare and very rare side effects might be serious	Skin rash with blisters; hives	~	~
	Wheezing, shortness of breath or feeling of tightness in the chest (asthma)	~	~
	Swelling of the face, lips, tongue or throat	✓	~
Common	Skin rash, itching, reddening or smarting of the skin		~

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM				
Symptom /	effect	Talk with your doctor or pharmaci st	Stop taking drug and call your doctor or pharmacis t	
Very rare side effects	The skin may be more sensitive to the sun. Possible signs are sunburn with itching, swelling and blistering	~	*	

This is not a complete list of side effects. For any unexpected effects while taking **Voltaren Emulgel** contact your doctor or pharmacist.

HOW TO STORE IT

Voltaren Emulgel should be stored between 15°C and 30°C.

Voltaren Emulgel should not be stored after the expiry date shown on the carton and tube.

Do not use **Voltaren Emulgel** after the expiry date stated on the label.

Keep Voltaren Emulgel out of the reach and sight of children.

REPORTING SIDE EFFECTS

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (http://www.hc-sc.gc.ca/dhpmps/medeff/report-declaration/indexeng.php) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals, can be received by contacting the sponsor, GlaxoSmithKline Consumer Healthcare Inc., at: 1-888-788-8181 www.voltaren.ca

GlaxoSmithKline Consumer Healthcare Inc., Mississauga, Ont., L5N 6L4. Trademarks are owned by or licensed to GSK group of companies. © 2018 GSK group of companies or its licensor

This leaflet was prepared by GlaxoSmithKline Consumer Healthcare Inc.

Last revised: March 4, 2020

PART III: CONSUMER INFORMATION

Voltaren Emulgel Back & Muscle Pain Diclofenac diethylamine gel 11.6 mg/g (1.16% w/w) (with and without No Mess Applicator)

This leaflet is part III of a three-part "Product Monograph" published when **Voltaren Emulgel** Back & Muscle Pain was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about **Voltaren Emulgel** Back & Muscle Pain.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- Contact your doctor or pharmacist if you have any questions about the drug or need more information or advice.

Separate Product Monograph available for VOLTAREN EMULGEL Extra Strength and VOLTAREN EMULGEL Joint Pain Extra Strength (Diclofenac diethylamine Gel, 23.2 mg/g /2.32% w/w)

ABOUT THIS MEDICATION

What the medication is used for:

Voltaren Emulgel Back & Muscle Pain

For the relief pain associated with recent (acute), localized minor muscle or joint injuries such as sprains, strains or sports injuries (e.g. sprain of ankle, strain of shoulder or back muscles). This is typically as an adjunct to other measures such as rest for the relief of discomfort associated with such injuries

What it does:

Voltaren Emulgel Back & Muscle Pain is specially formulated for rubbing into the skin to relieve acute pain affecting the joints and muscles. The active substance, diclofenac, is one of the groups of medicines called non-steroidal anti-inflammatory drugs (NSAIDs) that work within the body by blocking the production of particular substances, called prostaglandins, which are involved in the development of pain and inflammation.

When it should not be used:

- If you are currently taking diclofenac or any other over-the-counter or prescription oral non-steroidal anti-inflammatory drug (NSAID) which are used to treat pain, fever or inflammation, such as ibuprofen, acetylsalicylic acid (ASA) or naproxen. If you are not sure, ask your doctor or pharmacist.
- If in the past you have had allergic reactions to diclofenac or any other NSAIDs such as ibuprofen, ASA or naproxen.
- If you have attacks of asthma, urticaria (hives), or acute rhinitis (nasal inflammation, irritation or stuffy nose that lasts less than 6 weeks), swelling of the face or tongue, runny nose after taking ASA or other NSAIDs
- If you are allergic to any of the nonmedicinal ingredients in the gel (see list of nonmedicinal ingredients).
- If you are in the last 3 months of pregnancy as it could harm your unborn child or cause problems at delivery.
- Do not use right before or after heart surgery.

If any of these applies to you, do not use this medicine. If you are not sure, ask your doctor or pharmacist.

What the medicinal ingredient is:

Diclofenac diethylamine

What the nonmedicinal ingredients are:

Voltaren Emulgel Back & Muscle Pain 1.16% w/w gel contains the following nonmedicinal ingredients: Carbomer, cocoyl caprylocaprate, diethylamine, fragrance (containing benzyl benzoate), isopropyl alcohol, liquid paraffin, macrogol cetostearyl ether, propylene glycol, purified water.

Propylene glycol and benzyl benzoate, may cause mild localized skin irritation in some people.

What dosage forms it comes in:

Voltaren Emulgel Back & Muscle Pain 1.16% w/w gel comes in tubes of 20 g, 30 g, 50 g, 100 g, and 150 g.

Voltaren Emulgel Back & Muscle Pain 1.16% w/w gel (with No Mess Applicator) comes in tubes of 120 g.

The gel is white to practically white, cooling, nongreasy, non-staining, cream-like.

WARNINGS AND PRECAUTIONS

BEFORE you use **Voltaren Emulgel** Back & Muscle Pain talk to your doctor or pharmacist if:

- You have a history of stomach ulcers or take medication for such gastrointestinal disorders.
- You are pregnant, or think you may be pregnant, or are planning to have a baby, or are breast feeding.
- You are taking, or have recently taken, any other medicines, including Over the Counter drugs.

PROPER USE OF THIS MEDICATION

Voltaren Emulgel Back & Muscle Pain is not <u>intended</u> for use in children under the age of 16.

Do not apply to cuts or open wounds, or to skin that has a rash or eczema. Discontinue the treatment if a skin rash develops after applying the product.

Avoid applying on large areas of skin, or for a longer than approved duration of use, unless under medical advice.

A brace or wrap commonly used for injuries like sprains can be used but do not wrap the skin with an airtight (plastic) or occlusive dressing when using **Voltaren Emulgel** Back & Muscle Pain.

In very rare cases, your skin may be more sensitive to sunlight while using this product. Use caution during sun exposure or when using tanning booths/sun lamps. Possible signs are sunburn with itching, swelling and blistering.

Be careful not to get it in your eyes. If this happens, rinse your eyes well with clean water and tell a doctor or a pharmacist. **Voltaren Emulgel** Back & Muscle Pain is for EXTERNAL USE ONLY.

Do not use it in the mouth, vaginal or anal areas.

Never swallow it.

INTERACTIONS WITH THIS MEDICATION

Check with your doctor or pharmacist if you are taking any other NSAIDs (e.g. ibuprofen, acetylsalicylic acid or naproxen) or anticoagulants (blood thinners), high blood pressure medication, oral anti-diabetic agents, fluoroquinolone antibiotics (*i.e.*, ofloxacin) or are taking medication for peptic ulcers, gastroesophageal disease or to control excess acidity. If you suspect a drug interaction, notify your doctor or pharmacist.

Usual dose:

Voltaren Emulgel Back & Muscle Pain:

For adults and adolescents 16 years and older (regular strength):

- Apply gel 3 to 4 times a day on the affected area.
- The amount needed will vary depending upon the size of the painful or swollen area: 2 g to 4 g (1 g equals a strip approximately 2 cm long) gel will be sufficient to cover a 400 to 800 cm² area. Do not use more than 4 times in 24 hours.
- Tubes: To remove the security seal before first use, remove the cap off the tube (see figure 1)
- Figure 1:




- Tube: (See figure 1) Firmly insert the star-shape groove located on the reverse side of the cap into the star-shaped security seal of the tube.
- Tube: (See figure 1) Firmly turn the cap to remove the security seal from the tube.
- Tube: gently squeeze out a small amount of gel from the tube and apply to the affected area, slowly rubbing into the skin.
- You may notice a slight cooling effect when you rub the gel in.
- Tube: (See figure 1) After use, place the cap back on the tube and store in an upright position.
- Applicator: (See figure 2) To remove the seal before first use, remove the transparent protective cover and then unscrew the applicator cap. Use the star-shape groove (the key) located at the side of the applicator cap to remove the security seal (star seal) of the tube. Screw the applicator cap back on the tube before dispensing the gel.
- Applicator: (See figure 2) To open, simply pull the white part of the applicator cap. Gently squeeze the tube to push the gel to the surface of the applicator cap. Use the applicatorcapped tube as you would be your fingers to gently and slowly rub the gel into the skin on the affected area. The slight pressure of rubbing in the gel will automatically close the applicator cap.
- You may notice a slight cooling effect when you rub the gel in.
- <u>Applicator:</u> (See figure 2) After use, clean the applicator cap with cotton towel or absorbent paper until visually dry and clean. Do not immerse or rinse under water. Do not use any solvent or detergent to clean the surface of the applicator cap. After cleaning, place the transparent protective cap back on the tube before storage. Do not reuse the applicator cap with another tube. Discard the tube with its applicator cap following the recommended procedure for the disposal of any medication.

• Wash your hands after rubbing in Voltaren Emulgel Back & Muscle Pain to avoid accidental contact with the mouth and eyes.

The gel should not be used for more than 7 days for muscle and joint injuries unless recommended by a doctor. Talk to your doctor if your condition does not improve within 7 days, or if it gets worse.





Overdose:

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

If you dispense more gel than needed, wipe off the surplus gel with a tissue.

If you, or a child accidentally swallows the gel, contact your doctor immediately.

Missed Dose:

If you miss applying **Voltaren** Back & Muscle Pain at the correct time, apply it when you remember and then next apply it at the usual time. Do not apply a double quantity.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Itching, reddening or slight irritation of the skin are common after use of **Voltaren Emulgel** Back & Muscle Pain. These symptoms are usually mild, passing and harmless. If you are concerned, tell a doctor or pharmacist. Discontinue the treatment if a skin rash develops after applying the product.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom /	effect	Talk with your doctor or pharmaci st	Stop taking drug and call your doctor or pharmacis t		
Some rare and very rare side effects might be serious	Skin rash with blisters; hives	~	✓		
	Wheezing, shortness of breath or feeling of tightness in the chest (asthma)	~	✓		
	Swelling of the face, lips, tongue or throat	~	✓		
Common	Skin rash, itching, reddening or smarting of the skin		√		

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom / effect		Talk with your doctor or pharmaci st	Stop taking drug and call your doctor or pharmacis t
Very rare side effects	The skin may be more sensitive to the sun. Possible signs are sunburn with itching, swelling and blistering	~	•

This is not a complete list of side effects. For any unexpected effects while taking **Voltaren Emulgel** Back & Muscle Pain contact your doctor or pharmacist.

HOW TO STORE IT

Voltaren Emulgel Back & Muscle Pain should be stored between 15°C and 30°C.

Voltaren Emulgel **Back & Muscle Pain** should not be stored after the expiry date shown on the carton and tube.

Do not use **Voltaren Emulgel** Back & Muscle Pain after the expiry date stated on the label.

Keep Voltaren Emulgel Back & Muscle Pain out of the reach and sight of children.

REPORTING SIDE EFFECTS

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (http://www.hc-sc.gc.ca/dhpmps/medeff/report-declaration/indexeng.php) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals, can be received by contacting the sponsor, GlaxoSmithKline Consumer Healthcare Inc., at: 1-888-788-8181 www.voltaren.ca

GlaxoSmithKline Consumer Healthcare Inc., Mississauga, ON., L5N 6L4. Trademarks are owned by or licensed to GSK group of companies. © 2018 GSK group of companies or its licensor.

This leaflet was prepared by GlaxoSmithKline Consumer Healthcare Inc.

Last revised: March 4, 2020

PART III: CONSUMER INFORMATION

Voltaren Emulgel Joint Pain Regular Strength Diclofenac diethylamine gel 11.6 mg/g (1.16% w/w)

This leaflet is part III of a three-part "Product Monograph" published when **Voltaren Emulgel** Joint Pain Regular Strength was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about **Voltaren Emulgel** Joint Pain Regular Strength.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- Contact your doctor or pharmacist if you have any questions about the drug or need more information or advice.

Separate Product Monograph available for VOLTAREN EMULGEL Extra Strength and VOLTAREN EMULGEL Joint Pain Extra Strength (Diclofenac diethylamine Gel, 23.2 mg/g /2.32% w/w)

ABOUT THIS MEDICATION

What the medication is used for:

Voltaren Emulgel Joint Pain Regular Strength

For the relief pain associated with recent (acute), localized minor muscle or joint injuries such as sprains, strains or sports injuries (e.g. sprain of ankle, strain of shoulder or back muscles). This is typically as an adjunct to other measures such as rest for the relief of discomfort associated with such injuries

What it does:

Voltaren Emulgel Joint Pain Regular Strength is specially formulated for rubbing into the skin to relieve acute pain affecting the joints and muscles. The active substance, diclofenac, is one of the group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs) that work within the body by blocking the production of particular substances, called prostaglandins, which are involved in the development of pain and inflammation.

When it should not be used:

- If you are currently taking diclofenac or any other oral non-steroidal anti-inflammatory drug (NSAID) which are used to treat pain, fever or inflammation, such as ibuprofen or acetylsalicylic acid (ASA). If you are not sure, ask your doctor or pharmacist.
- If in the past you have had allergic reactions to diclofenac or any other NSAIDs such as ibuprofen or ASA or naproxen.
- If you have attacks of asthma, urticaria (hives), or acute rhinitis (nasal inflammation, irritation or stuffy nose that lasts less than 6 weeks), swelling of the face or tongue or runny nose after taking ASA or other NSAIDs.
- If you are allergic to any of the nonmedicinal ingredients in the gel (see list of nonmedicinal ingredients).
- If you are in the last 3 months of pregnancy as it could harm your unborn child or cause problems at delivery.
- Do not use right before or after heart surgery.

If any of these applies to you, do not use this medicine. If you are not sure, ask your doctor or pharmacist.

What the medicinal ingredient is:

Diclofenac diethylamine

What the nonmedicinal ingredients are:

Voltaren Emulgel Joint Pain Regular Strength 1.16% w/w gel contains the following nonmedicinal ingredients: Carbomer, cocoyl caprylocaprate, diethylamine, fragrance (containing benzyl benzoate), isopropyl alcohol, liquid paraffin, macrogol cetostearyl ether, propylene glycol, purified water.

Propylene glycol and benzyl benzoate, may cause mild localized skin irritation in some people.

What dosage forms it comes in:

Voltaren Emulgel Joint Pain Regular Strength 1.16

w/w gel comes in a tube of 120g.

The gel is white to practically white, cooling, nongreasy, non-staining, cream-like gel.

WARNINGS AND PRECAUTIONS

BEFORE you use **Voltaren Emulgel** Joint Pain Regular Strength talk to your doctor or pharmacist if:

- You have a history of stomach ulcers or take medication for such gastrointestinal disorders.
- You are pregnant, think you may be pregnant, or are planning to have a baby, or breast feeding.
- You are taking, or have recently taken, any other medicines, including Over the Counter drugs.

Voltaren Emulgel Joint Pain Regular Strength is <u>not</u> <u>intended</u> for use in children under the age of 16.

Do not apply to cuts or open wounds or to skin that has a rash or eczema. Discontinue the treatment if a skin rash develops after applying the product.

Avoid applying on large areas of skin or for a longer than approved duration of use, unless under medical advice.

A brace or wrap commonly used for injuries like sprains can be used but do not wrap the skin with an airtight (plastic) or occlusive dressing when using **Voltaren Emulgel** Joint Pain Regular Strength.

In very rare cases, your skin may be more sensitive to sunlight while using this product. Use caution during sun exposure or when using tanning booths/sun lamps. Possible signs are sunburn with itching, swelling and blistering.

Be careful not to get it in your eyes. If this happens, rinse your eyes well with clean water and tell a doctor or a pharmacist.

Voltaren Emulgel Joint Pain Regular Strength is for EXTERNAL USE ONLY.

Do not use it in the mouth, vaginal or anal areas. Never swallow it.

INTERACTIONS WITH THIS MEDICATION

Check with your doctor or pharmacist if you are taking any other NSAIDs (ibuprofen or acetylsalicylic acid) or anticoagulants (blood thinners), high blood pressure medication, oral anti-diabetic agents, fluoroquinolone antibiotics (*i.e.*, ofloxacin) or are taking medication for peptic ulcers, gastroesophageal disease or to control excess acidity. If you suspect a drug interaction, notify your doctor or pharmacist.

PROPER USE OF THIS MEDICATION

Usual dose:

Voltaren Emulgel Joint Pain Regular Strength For adults and adolescents 16 years and older (regular strength):

- Apply gel 3 to 4 times a day on the affected area.
- The amount needed will vary depending upon the size of the painful or swollen area: 2 g to 4 g (1 g equals a strip approximately 2 cm long) gel will be sufficient to cover a 400 to 800 cm² area. Do not use more than 4 times in 24 hours.
- Tube: (See figure 1) To remove the security seal before first use, remove the cap off the tube. Tube: (See figure 1) Firmly insert the star-shape groove located on the reverse side of the cap into the star-shaped security seal of the tube
- Tube: (See figure 1) Firmly turn the cap to remove the security seal from the tube
- Tube: gently squeeze out a small amount of gel from the tube and apply to the affected area, slowly rubbing into the skin.
- You may notice a slight cooling effect when you rub the gel in.
- Tube: (See figure 1) After use, place the cap back on the tube and store in an upright position.
- Wash your hands after rubbing in **Voltaren Emulgel** Joint Pain Regular Strength to avoid accidental contact with the mouth and eyes.

The gel should not be used for more than 7 days for muscle and joint injuries, unless recommended by a doctor. Talk to your doctor if your condition does not improve within 7 days, or if it gets worse. Figure 1:



Overdose:

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

If you dispense more gel than needed wipe off the surplus gel with a tissue.

If you or a child accidentally swallows the gel, contact your doctor immediately.

Missed Dose:

If you miss applying **Voltaren Emulgel** Joint Pain Regular Strength at the correct time, apply it when you remember and then next apply it at the usual time. Do not apply a double quantity.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Itching, reddening or slight irritation of the skin are common after use of **Voltaren Emulgel** Joint Pain Regular Strength. These symptoms are usually mild, passing and harmless. If you are concerned, tell a doctor or pharmacist. Discontinue the treatment if a skin rash develops after applying the product.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom / effect	Talk with	Stop taking
	your	drug and
	doctor or	call your
	pharmacist	doctor or
		pharmacist

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom / effect		Talk with your doctor or pharmacist	Stop taking drug and call your doctor or pharmacist
Some rare and very rare side effects might be serious	Skin rash with blisters; hives	~	~
	Wheezing, shortness of breath or feeling of tightness in the chest (asthma)	~	~
	Swelling of the face, lips, tongue or throat	~	✓
Common	Skin rash, itching, reddening or smarting of the skin	~	✓
Very rare side effects	The skin may be more sensitive to the sun. Possible signs are sunburn with itching, swelling and blistering		

This is not a complete list of side effects. For any unexpected effects while taking **Voltaren Emulgel** Joint Pain Regular Strength, contact your doctor or pharmacist.

HOW TO STORE IT

Voltaren Emulgel Joint Pain Regular Strength should be stored between 15°C and 30°C.

Voltaren Emulgel Joint Pain Regular Strength should not be stored after the expiry date shown on the carton and tube. Do not use after the expiry date stated on the label

Keep Voltaren Emulgel Joint Pain Regular Strength out of the reach and sight of children.

REPORTING SIDE EFFECTS

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (http://www.hc-sc.gc.ca/dhpmps/medeff/report-declaration/indexeng.php) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals, can be received by contacting the sponsor, GlaxoSmithKline Consumer Healthcare Inc., at: 1-888-788-8181 www.voltaren.ca

GlaxoSmithKline Consumer Healthcare Inc., Mississauga, ON., L5N 6L4. © 2018 GSK group of companies or its licensor. All rights reserved. This leaflet was prepared by **GlaxoSmithKline** Consumer Healthcare Inc.

Last revised: March 4, 2020